About
Goldenrod Therapeutics is developing next-generation, brain-penetrant phosphodiesterase 4 (PDE4) inhibitors for multiple neurological indications, including Friedreich’s ataxia, other neurodegenerative diseases, substance use disorders, and pain. Their oral, small molecule drugs are designed for high central nervous system exposure and improved tolerability, aiming to address significant unmet medical needs.
Technology stack
detected 2026-06-04Est. monthly stack spend~$100/mo
Email
Google Workspace
Stack
Squarespace
SquarespaceFrequently asked
What does Goldenrod Therapeutics, . do?
Goldenrod Therapeutics is developing next-generation, brain-penetrant phosphodiesterase 4 (PDE4) inhibitors for multiple neurological indications, including Friedreich’s ataxia, other neurodegenerative diseases, substance use disorders, and pain. Their oral, small molecule drugs are designed for high central nervous system exposure and improved tolerability, aiming to address significant unmet medical needs.
How much funding has Goldenrod Therapeutics, . raised?
Goldenrod Therapeutics, . has raised a total of $1M in funding. The most recent round on record is Seed.
Where is Goldenrod Therapeutics, . headquartered?
Goldenrod Therapeutics, . is headquartered in San Diego, United States.
When was Goldenrod Therapeutics, . founded?
Goldenrod Therapeutics, . was founded in 2017.
What industry does Goldenrod Therapeutics, . operate in?
Goldenrod Therapeutics, . operates in Biotech, Drug Discovery, HealthTech, Rare Diseases, Therapeutics.